Novo Nordisk

Novo Nordisk’s Pipeline Gains Traction as Zenagamtide Data and CagriSema Filing Drive Investor Focus

kashif hafeez -

Novo Nordisk Faces a Defining Quarter: Medicare Catalyst Clashes With Cyber Attack and Profit Squeeze

angelina -

Novo Nordisk: Pill Uptake and Pipeline Catalysts Vie to Eclipse a Cyber Incident

angelina -

Novo Nordisk: A Stock Punished by the Past While a Pill Reshapes the Future

kashif hafeez -

Novo Nordisk’s Real-World Retort and a Muscle-Preserving Alliance: The ADA Story

Novo Nordisk Braces for Defining Week as Medicare Deal and Phase 3 CagriSema Data Converge

Wegovy Pill’s Quick Start Sets Stage for Novo Nordisk’s Next Data Catalyst

Novo Nordisk: A New Indication Beckons Even as Patent Walls Crumble in Emerging Markets

kashif hafeez -

Novo Nordisk’s Pipeline Hope Meets Commercial Reality: India Clearance and CVS Reversal Collide

Catalysts and Clouds Collide for Novo Nordisk: Oral Wegovy Nears EU Launch While Safety Study Spurs Caution

Brett Shapiro -

Novo Nordisk Juggles Pipeline Ambitions and Pill Expansion as Profit Pressure Mounts

angelina -

Novo Nordisk Lifts Guidance on Oral Wegovy Adoption and Compelling Fat-Loss Data

Novo Nordisk Tightens Domestic Operations as Obesity Pipeline Gathers Momentum

kashif hafeez -

At Istanbul Congress, Novo Nordisk Unveils Data Blitz While Oral Wegovy Races Past 2 Million Prescriptions

Novo Nordisk’s Logistics Win Offers a Lift, but the Washington Headache Is Just Beginning

123Page 1 of 3